Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback